In a report published on Monday, the World Health Organization (WHO) said that beta lactams antibiotics are likely to be a cause of antibiotic resistance and that they should be considered for human use only in patients with a documented allergy or immunocompromised condition.
The WHO also said that they can also be used for use as an alternative to beta lactamic acid antibiotics, which have a lower efficacy rate.
“Beta lactam is an important antibiotic that has shown promise as an antibiotic in several clinical trials, including in colitis and acute respiratory infections,” said Dr. James D. Akey, WHO Director of Public Health, in a press release.
“The WHO recommends that beta glucams antibiotics be considered only in a patient with a confirmed allergy or immune compromised condition and who has a documented history of drug use.”
Beta lactams are the second-most used antibiotics in the world after penicillin.
According to the WHO, the production of beta lactama drugs is responsible for over 10 percent of the worldwide market.
Beta lactam drugs are also the most frequently used beta-lactam antibiotics in clinical trials.
However, according to the report, the drugs have been linked to a number of side effects, including kidney damage, urinary tract infections, urinary retention, skin rashes, and pneumonia.
One study published in the Lancet Medical Publishing Group found that beta-glucam antibiotics are more likely to cause urinary tract infection and urinary retention than the antibiotic beta lactamate.
Another study published by the journal BMJ also found that the use of beta- lactam can result in an increase in urinary tract bacterial overgrowth.
This overgrowth can lead to urinary tract and bladder infections and lead to a reduction in the effectiveness of beta glucam antibiotics.
The report also found the beta lactaminase inhibitor linalool had higher mortality and hospitalizations than the beta glucaminase inhibitors azithromycin and metronidazole.
Beta-glaucam antibiotics were previously prescribed to prevent infections caused by Salmonella typhi, a bacteria that can be transmitted to humans from dogs and cats.
The beta lactameres are also used as an adjuvant in the treatment of tuberculosis and pneumonia in humans.
The United States has seen a spike in cases of the bacteria from dogs since the mid-2000s.
This spike in canine cases has caused some concern that beta lactam could be contributing to the rise in tuberculosis cases.
However the report did note that there is no evidence to support this claim.
According the WHO’s report, there is currently no evidence that beta beta lactamines are linked to any increased incidence of tuberculosis in humans, even though beta lactami may be used in conjunction with beta lactamus antibiotics.